Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.
Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Among authors: heath ei. Prostate Cancer Prostatic Dis. 2024 Feb 28. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Antonarakis ES, et al. Among authors: heath ei. J Clin Oncol. 2009 Oct 20;27(30):4986-93. doi: 10.1200/JCO.2009.21.9410. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720908 Free PMC article. Clinical Trial.
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. Antonarakis ES, et al. Among authors: heath ei. Cancer Chemother Pharmacol. 2013 Apr;71(4):883-92. doi: 10.1007/s00280-013-2079-z. Epub 2013 Jan 13. Cancer Chemother Pharmacol. 2013. PMID: 23314737 Free PMC article. Clinical Trial.
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.
Antonarakis ES, Heath EI, Smith DC, Rathkopf D, Blackford AL, Danila DC, King S, Frost A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA. Antonarakis ES, et al. Among authors: heath ei. Oncologist. 2013;18(2):163-73. doi: 10.1634/theoncologist.2012-314. Epub 2013 Jan 22. Oncologist. 2013. PMID: 23340005 Free PMC article. Clinical Trial.
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY. Cheng HH, et al. Among authors: heath ei. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53. Epub 2015 Jan 20. Prostate Cancer Prostatic Dis. 2015. PMID: 25600186 Free PMC article.
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI. Thakur MK, et al. Among authors: heath ei. Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18. Invest New Drugs. 2016. PMID: 26581400 Free PMC article. Clinical Trial.
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ. McHugh D, et al. Among authors: heath ei. Invest New Drugs. 2019 Oct;37(5):1052-1060. doi: 10.1007/s10637-019-00731-5. Epub 2019 Feb 6. Invest New Drugs. 2019. PMID: 30725389 Free PMC article. Clinical Trial.
The current state of molecular testing in the treatment of patients with solid tumors, 2019.
El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL. El-Deiry WS, et al. Among authors: heath ei. CA Cancer J Clin. 2019 Jul;69(4):305-343. doi: 10.3322/caac.21560. Epub 2019 May 22. CA Cancer J Clin. 2019. PMID: 31116423 Free PMC article. Review.
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group. Paller CJ, et al. Among authors: heath ei. Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. doi: 10.1016/j.clgc.2019.04.013. Epub 2019 Apr 18. Clin Genitourin Cancer. 2019. PMID: 31171481 Free PMC article.
212 results